Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rapt Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: https://www.rapt.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Brian Russell Wong, MD, PhD
Number Of Employees: 68
Enterprise Value: $-162,160,394
PE Ratio: -0.36
Exchange/Ticker 1: NASDAQ:RAPT
Exchange/Ticker 2: N/A
Latest Market Cap: $146,527,808
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Dec 31, 2024
Finance
Biotech raises make 2024 the year of the PIPE
BioCentury’s final Public Equity Report of the year tallies up fundraising activity
BioCentury | Nov 13, 2024
Product Development
Adverse event casts shadow over Neurogene’s Rett syndrome readout
BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Feb 21, 2024
Product Development
Clinical report: Latest setback in RIPK1 program for Denali, Sanofi
Plus: RAPT’s clinical hold, Tagrisso’s latest readout
BioCentury | Feb 16, 2024
Management Tracks
CEO Hanson leaving enGene
Plus: Compugen names Mahler CMO and updates from Merck, Navega, RAPT and Ocuphire
BioCentury | Nov 19, 2022
Market Access
Nov. 18 Quick Takes: Provention prices first-ever therapy to delay diabetes progression
Plus: Apellis shares bounce as FDA accepts amended NDA, and updates from Iovance, RAPT, G1, Lysogene and RongCan
BioCentury | Sep 29, 2022
Management Tracks
Kevin Bunker promoted to CSO at Zentalis
Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
BioCentury | May 5, 2022
Management Tracks
Adaptimmune veteran Brewer now CSO
Plus updates from Fulgent, Enthera, UCSF, Anji and RAPT
BioCentury | Sep 10, 2021
Targets & Mechanisms
Integrated stress response key to seemingly disparate diseases?
A flurry of preclinical studies builds the case for the integrated stress response as a central driver of many diseases
BioCentury | Jun 14, 2021
Product Development
June 14 Quick Takes: Biogen’s Nightstar acquisition falls flat with second gene therapy failure; plus RAPT, Terns, Amylyx, Avenue and more
Biogen Inc. (NASDAQ:BIIB) announced the company’s second late-stage failure for an ophthalmic gene therapy in the past month on Monday when the biopharma said timrepigene emparvovec
Items per page:
1 - 10 of 26